Literature DB >> 33984405

Kidney-Related Research in the United States: A Position Statement From the National Kidney Foundation and the American Society of Nephrology.

Ryan Murray1, Troy Zimmerman2, Anupam Agarwal3, Paul M Palevsky4, Susan Quaggin5, Sylvia E Rosas6, Holly Kramer7.   

Abstract

Kidney disease is an important US public health problem because it affects over 37 million Americans, and Medicare expenditures for patients with chronic kidney disease now alone exceed $130 billion annually. Kidney disease is characterized by strong racial, ethnic, and socioeconomic disparities, and reducing kidney disease incidence will positively impact US health disparities. Due to the aging of the US population and an unabated obesity epidemic, the number of patients receiving treatment for kidney failure is anticipated to increase, which will escalate kidney disease health expenditures. The historical and current investment in kidney-related research via the National Institute of Diabetes and Digestive and Kidney Diseases has severely lagged behind ongoing expenditures for kidney disease care. Increasing research investment will identify, develop, and increase implementation of interventions to slow kidney disease progression, reduce incidence of kidney failure, enhance survival, and improve quality of life. This perspective states the urgent reasons why increasing investment in kidney-related research is important for US public health. The National Kidney Foundation and the American Society of Nephrology are working together to advocate for increased funding for the National Institute of Diabetes and Digestive and Kidney Diseases. The long-term goal is to reduce the burden of kidney disease in the US population and improve the quality of life of patients living with kidney disease. Published by Elsevier Inc.

Entities:  

Keywords:  Kidney disease; end-stage kidney disease (ESKD); health care policy; health disparities; population health; public health; race disparities; research; research funding

Mesh:

Year:  2021        PMID: 33984405     DOI: 10.1053/j.ajkd.2021.04.006

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

1.  Fostering Scientific Innovation to Impact AKI: A Roadmap from ASN's AKINow Basic Science Workgroup.

Authors:  Samir M Parikh; Anupam Agarwal; Amandeep Bajwa; Sanjeev Kumar; Sherry G Mansour; Mark D Okusa; Jorge Cerda
Journal:  Kidney360       Date:  2022-06-17

2.  CKD: The burden of disease invisible to research funders.

Authors: 
Journal:  Nefrologia (Engl Ed)       Date:  2022 Jan-Feb

3.  CKD: The burden of disease invisible to research funders.

Authors: 
Journal:  Nefrologia       Date:  2021-11-17       Impact factor: 2.033

4.  RICORS2040: the need for collaborative research in chronic kidney disease.

Authors:  Alberto Ortiz
Journal:  Clin Kidney J       Date:  2021-09-23

5.  Education Standards for Pharmacists Providing Comprehensive Medication Management in Outpatient Nephrology Settings.

Authors:  Joanna Q Hudson; Rebecca Maxson; Erin F Barreto; Katherine Cho; Amanda J Condon; Elizabeth Goswami; Jean Moon; Bruce A Mueller; Thomas D Nolin; Heather Nyman; A Mary Vilay; Calvin J Meaney
Journal:  Kidney Med       Date:  2022-06-25

Review 6.  Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.

Authors:  Ben Sprangers; Mark A Perazella; Stuart M Lichtman; Mitchell H Rosner; Kenar D Jhaveri
Journal:  Kidney Int Rep       Date:  2022-06-15

7.  Editorial: Hypertension and Chronic Kidney Injury or Failure, Volume II.

Authors:  Zhengrong Guan; Suttira Intapad; Oleg Palygin; Jennifer C Sullivan
Journal:  Front Physiol       Date:  2022-01-07       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.